Factors impacting the results of interferon-γ release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases

Inflammatory Bowel Diseases

Volumn 17, Issue 1, 2011, Pages 84-90

  Papay, Pavol ^a   Eser, Alexander ^a   Winkler, Stefan ^b   Frantal, Sophie ^a   Primas, Christian ^a   Miehsler, Wolfgang ^a   Novacek, Gottfried ^a   Vogelsang, Harald ^a   Dejaco, Clemens ^a   Reinisch, Walter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

IM therapy; inflammatory bowel disease; interferon release assay; latent tuberculosis; tuberculin skin test

Indexed keywords

GAMMA INTERFERON; INFLIXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; BCG VACCINATION; CROHN DISEASE; DRUG SCREENING; ENTERITIS; FEMALE; HUMAN; IMMUNOMODULATION; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; THORAX RADIOGRAPHY; TUBERCULIN TEST; ULCERATIVE COLITIS;

ADULT; COHORT STUDIES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA; LATENT TUBERCULOSIS; MALE; MASS SCREENING; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; RADIOGRAPHY, THORACIC; TUBERCULIN TEST;

EID: 78650079955     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21427     Document Type: Article

References (35)

1. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004; 38: 1261-1265.
2. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies, Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006; 295: 2275-2285.
3. Viget N, Vernier-Massouille G, Salmon-Ceron D, et al. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut. 2008; 57: 549-558.
4. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent. N Engl J Med. 2001; 345: 1098-1104.
5. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis alpha inhibitors may predispose to significant increase in tuberculosis risk: a multi-center active-surveillance report. Arthritis Rheum. 2003; 48: 2122-2127.
6. Furst DE, Cush J, Kaufmann S, et al. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis. 2002; 61 (suppl 2) ii62-63.
7. Horsburgh CR Jr,. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004; 350: 2060-2067.
8. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis. 2009; 3: 47-91.
9. Pai M, Riley LW, Colford JM Jr, et al. Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004; 4: 761-766.
10. Mow WS, Abreu-Martin MT, Papadakis KA, et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol. 2004; 2: 309-313.
11. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, et al. Attenuated response to purified protein derivate in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis. 2005; 64: 1360-1361.
12. Mazurek GH, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005; 54: 49-55.
13. Menzies D, Pai M, Comstock G, et al. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainity and recommendations for research. Ann Intern Med. 2007; 146: 340-354.
14. Pai M, Kalantri S, Dheda K, New tools and emerging technologies for the diagnosis of tuberculosis: Part 1. Latent tuberculosis. Expert Rev Mol Diagn. 2006; 6: 413-422. (Pubitemid 44174345)
15. Sellam J, Hamdi H, Roy C, et al. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis. 2007; 66: 1610-1615.
16. Matulis G, Jüni P, Villiger PM, et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon γ assay. Ann Rheum Dis. 2008; 67: 84-90.
17. Schoepfer AM, Flogerzi B, Fallegger S, et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel diseases. Am J Gastroenterol. 2008; 103: 2799-2806.
18. Piana F, Codesaca LR, Besozzi G, et al. Use of commercial interferon-gamma assays in immunocompromised patients for tuberculosis diagnosis. Am J Respir Crit Care Med. 2006; 173: 130-131.
19. Ferrara G, Losi M, D'Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet. 2006; 367: 1328-1334.
20. Travis SP, Stange EF, Lémann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006; 55 (suppl I) i16-i35.
21. Stange EF, Travis SP, Vermiere S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006; 55 (suppl I): i1-i15.
22. Silverberg MS, Satsangi J, Ahmad T, et al. Towards an integrated clinical, molecular, and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 (suppl A): 5A-36A.
23. Oefferlbauer-Ernst A, Miehsler W, Reinisch W, et al, and the Austrian IBDIS group. Interobserver agreement analysis of a national Inflammatory Bowel Disease Information System (IBDIS). Gastroenterology. 2003; 124: A507.
24. Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut. 2006; 55 (suppl 1): i36-58.
25. Jasmer RM, Nahid P, Hopewell PC, et al. Latent tuberculosis infection. N Engl J Med. 2002; 347: 1860-1866.
26. Lee E, Holzman RS,. Evolution and current use of the tuberculin test. Clin Infect Dis. 2002; 34: 365-370.
27. AGES Tuberkulose Jahresbericht 2007,.
28. Ormerod LP, Millburn HJ, Gillespie S, et al. British Thoracic Society recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start antiTNF α treatment. Thorax. 2005; 60: 800-805.
29. Mazurek GH, LoBue PA, Daley CL, et al. Comparison of whole blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA. 2001; 286: 1740-1747.
30. Kang YA, Lee HW, Yoon HI, et al. Discrepancy between the tuberculin skin test and the whole blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA. 2005; 293: 2756-2761.
31. Takahashi H, Shigehara K, Yamamoto M, et al. Interferon γ assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration. Rheumatol Int. 2007; 27: 1143-1148.
32. Wang L, Turner MO, Elwood RK, et al. A meta-analysis of the effect of Bacille Calmette Guérin vaccination on tuberculin skin test measurements. Thorax. 2002; 57: 804-809.
33. Menzies D,. What does tuberculin reactivity after Bacille Calmette-Guérin vaccination tell us? Clin Infect Dis. 2000; 31 (suppl 3): S71-74.
34. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994; 35: 360-362.
35. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology. 2006; 130: 650-656.